NDA 019828 · Fougera
Oxistat
Oxiconazole Nitrate · Topical
NovelLast checked: Nov 20, 2026Latest source record: Jan 23, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 30, 1988
Approved uses
4
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 0 recruiting
FAERS reports
171
75 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 28, 2026.
INDICATIONS AND USAGE Oxiconazole nitrate cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. Oxiconazole nitrate cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Oxiconazole nitrate cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which oxiconazole nitrate cream has been shown to be effective rarely occur in children below the age of 12.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 18, 1997 Supplement 7 · Efficacy
- Aug 18, 1997 Supplement 3 · Efficacy
- Sep 30, 1992 Supplement 5 · Efficacy
- Dec 30, 1988 Original approval · Type 1 - New Molecular Entity
1 products under this application
- OXISTAT · OXICONAZOLE NITRATE EQ 1% BASE · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxiconazole Nitrate" as an intervention, any sponsor and status, largest first.
- A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01519752 · 661 participants · Start Nov 2011 · Primary completion Aug 2012
Drug: Oxiconazole Nitrate Cream 1%; Oxiconazole Nitrate Cream 1% (Oxistat®) and 1 more · For: Tinea Pedis
- Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstractPivotal-lookingCompleted
Hayat Abad Medical Complex, PeshawarGovernment (non-federal)
NCT07441005 · 386 participants · Start May 15, 2025 · Primary completion Oct 15, 2025
Drug: Topical Oxiconazole cream; Topical Clotrimazole cream · For: Tinea Cruris
Sites: Peshawar, Pakistan
- Comparative Study of Topical Oxiconazole 1% Cream Versus Clotrimazole 1% Cream in the Treatment of DermatophytosisPivotal-lookingCompleted
Shalamar Institute of Health SciencesAcademic, hospital or other
NCT07718685 · 164 participants · Start Jan 1, 2025 · Primary completion Jun 30, 2025
Drug: Oxiconazole Nitrate Cream; Clotrimazole Cream · For: Dermatophytoses
Sites: Lahore, Pakistan
Minia UniversityAcademic, hospital or other
NCT03823040 · 28 participants · Start Jul 16, 2018 · Primary completion Dec 23, 2018
Drug: Oxiconazole Nitrate Cream 1%; Oxiconazole nitrate SLNs loaded gel. · For: Tinea
Sites: Minya, Egypt
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective19
- rash16
- pruritus13
- arthralgia10
- headache10
- chronic kidney disease8
- erythema8
- nausea8
- pain7
- rash papular7
- renal failure7
- blister6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 4 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 10 |
| 2013 | 8 |
| 2014 | 7 |
| 2015 | 20 |
| 2016 | 17 |
| 2017 | 11 |
| 2018 | 15 |
| 2019 | 16 |
| 2020 | 15 |
| 2021 | 7 |
| 2022 | 16 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Oxistat (Oxiconazole Nitrate)
2024 spending
$246K
Beneficiaries
161
295 claims
Per beneficiary
$1,531
$14.39 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $251,070 |
| 2024 | $246,452 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis.
Elewski BE, Jones T, Zaias N · Cutis 1996 · Clinical Trial, Multicenter Study
- Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent.
Jegasothy BV, Pakes GE · Clin Ther 1991 · Clinical Trial, Comparative Study
- Evaluation of cutaneous reactivity to recently marketed dermatologic products.
Shelanski MV, Phillips SB, Potts CE · Int J Dermatol 1996 · Clinical Trial, Comparative Study
- Oxiconazole nitrate lotion, 1 percent: an effective treatment for tinea pedis.
Pariser DM, Pariser RJ · Cutis 1994 · Clinical Trial, Multicenter Study
- Oxiconazole nitrate solid lipid nanoparticles: formulation, in-vitro characterization and clinical assessment of an analogous loaded carbopol gel.
Mahmoud RA, Hussein AK, Nasef GA, et al. · Drug Dev Ind Pharm 2020 · Clinical Trial
- [The impact of concentrations of nitric oxide and activity of oxistat on development of inflammatory alterations in vascular wall].
NIkitina VV, Zakharova NB, Gladilin GP, et al. · Klin Lab Diagn 2014 · Controlled Clinical Trial, English Abstract
Sponsor: Fougera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.